Importantly, our results extend the therapeutic narrative of canagliflozin, this aligns with recent findings that canagliflozin upregulates PGC-1α to promote biogenesis and improve mitochondrial function in obesity and adipocytes, with beneficial effects beyond the regulation of glucose [38,39]. Here, PPARGC1A is linked to obesity due to melanocortin 4 receptor deficiency.